{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:44:47Z","timestamp":1776822287463,"version":"3.51.2"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["JNJ-42756493"],"award-info":[{"award-number":["JNJ-42756493"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013870","name":"Astex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clgc.2025.102376","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:38:02Z","timestamp":1747251482000},"page":"102376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4293-4680","authenticated-orcid":false,"given":"Earle F.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0391-2342","authenticated-orcid":false,"given":"Ja Hyeon","family":"Ku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2561-635X","authenticated-orcid":false,"given":"Yi-Hsiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Hemaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Deprince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5599-5393","authenticated-orcid":false,"given":"Spyros","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102376_bib0001","series-title":"International Agency for Research on Cancer","year":"2022"},{"key":"10.1016\/j.clgc.2025.102376_bib0002","article-title":"Globocan","volume":"2024","year":"2022"},{"key":"10.1016\/j.clgc.2025.102376_bib0003","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12967-020-02308-w","article-title":"Ethnicity and survival in bladder cancer: a population-based study based on the SEER database","volume":"18","author":"Fang","year":"2020","journal-title":"J Translation Med"},{"key":"10.1016\/j.clgc.2025.102376_bib0004","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Bladder cancer. Vol 2023. Version 3. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417 (Assessed June 5, 2024)."},{"key":"10.1016\/j.clgc.2025.102376_bib0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102376_bib0006","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102376_bib0007","unstructured":"The European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer. 2023. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer\/chapter\/disease-management (Assessed June 5, 2024)."},{"key":"10.1016\/j.clgc.2025.102376_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2025.102376_bib0009","article-title":"Frontiers in bladder cancer genomic research","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2025.102376_bib0010","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clgc.2025.102376_bib0011","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102376_bib0012","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.euf.2018.02.013","article-title":"Prognostic effect of FGFR mutations or gene fusions in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: results from a large, single-institution cohort","volume":"5","author":"Necchi","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2025.102376_bib0013","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2217\/fon-2016-0042","article-title":"A place for precision medicine in bladder cancer: targeting the FGFRs","volume":"12","author":"di Martino","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2025.102376_bib0014","unstructured":"BALVERSA\u00ae [prescribing information]. Horsham, PA: Janssen Products, LP. 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/BALVERSA-pi.pdf (Assessed June 5, 2024)."},{"key":"10.1016\/j.clgc.2025.102376_bib0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102376_bib0016","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102376_bib0017","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102376_bib0018","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12894-021-00876-7","article-title":"The incidence and prevalence of upper tract urothelial carcinoma: a systematic review","volume":"21","author":"Soualhi","year":"2021","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2025.102376_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/genes12030333","article-title":"Current knowledge on genomic profiling of upper tract urothelial carcinoma","volume":"12","author":"De Lorenzis","year":"2021","journal-title":"Genes (Basel)"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:31:29Z","timestamp":1762551089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732500076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S155876732500076X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102376","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102376"}}